Esbjerg

• A research study to look into the long-term effect on weight loss of CagriSema in people with obesity Ended recruitment
  2024-512144-39-00 5 2025-01-22 Obesity
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn … Ended recruitment
  2023-506457-38-00 5 2024-06-05 Chronic kidney disease (CKD) and hypertension.
• StayDry Ended recruitment
  2023-510280-35-00 6 2024-05-27 Daytime urinary incontinence
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended recruitment
  2022-502250-14-00 6 2023-04-13 Chronic rhinosinusitis with nasal polyposis
• Bicarbonate for the treatment of cardiac arrest Ended recruitment
  2022-501304-10-00 6 2023-02-06 In-hospital cardiac arrest
• A research study to see how well CagriSema helps people with excess body weight lose weight Ended recruitment
  2023-506929-11-00 5 2022-10-17 Overweight and obesity
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis Ended recruitment
  2024-514287-84-00 5 2021-04-28 Multiple sclerosis
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• MASTER Ended recruitment
  2024-515404-39-00 5 2021-01-14 Breast cancer
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• Oral vs Intravenous Fluids – healthy volunteers Ended
  2024-519656-85-00 3 2025-03-18 Hemodynamic parameters is to be investigated -- comparing intravenous
• Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID Ended
  2023-506949-27-00 4 2024-10-14 Secondary Osteoporosis

Showing 49–72 of 94 trials